CagA+ strains disrupt lipid metabolism, increasing non-alcoholic fatty liver disease, cardiovascular, and Alzheimer’s risks via PPAR interference, GBA1 demethylation, and altered FABP1/APOA1 expression, reversible by eradication. The gene discussed is FABP1; the disease is metabolic dysfunction-associated steatotic liver disease.